miR‐21 has been shown to drive chemoresistance by targeting PDCD4, PTEN or other genes in several solid tumours, such as renal carcinoma, hepatocellular carcinoma, colon carcinoma and gastric cancer cells.25, 26, 27. This evidence concerns the gene PDCD4 and colon carcinoma.